Anti-tumor protein isolated from ink of a sea slug destroys various kinds of cancers

11-Jul-2007

Celonic AG and APIT Laboratories GmbH have announced a commercial license agreement for of a new biopharmaceutical compound for the treatment of cancer. The anti-tumor protein, originally isolated from the defensive ink of a sea slug, attacks tumor cells in a threefold mechanism of action through the enzymatic production of reactive oxygen species and the deprivation of amino acids specifically required by tumor cells.

In vitro and in vivo experiments show that APIT efficiently destroys various kinds of cancers and could potentially also be used for the treatment of cancer becoming resistant to chemotherapy. This agreement grants Celonic the exclusive and worldwide rights for the development and marketing of the new pharmaceutical drug.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Sinochem To Acquire Butachlor and Alachlor Businesses In Certain Asian Countries And India From Monsanto

NextPharma inaugurates new production facility for liquid pharmaceuticals in Limay, France - "This project reflects our commitment to bringing the production of essential medicines back to France..."

NextPharma inaugurates new production facility for liquid pharmaceuticals in Limay, France - "This project reflects our commitment to bringing the production of essential medicines back to France..."

Camouflage mechanism of cancer cells in Hodgkin's lymphoma decoded - Curt Meyer Memorial Prize for Dr. Stephan Mathas and Dr. Martin Janz

Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma

European biotech industry identifies the real culprits causing food price rises

NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12

Key molecular interactions of the ZMapp anti-Ebola virus cocktail identified

4SC Announces Clinical Advancements in its Oncology Pipeline

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies

Why European Colonization Drove the Blue Antelope to Extinction - International team of scientists and start-up Colossal Biosciences decode the DNA of the bluebuck using state-of-the-art computer analysis software

Why European Colonization Drove the Blue Antelope to Extinction - International team of scientists and start-up Colossal Biosciences decode the DNA of the bluebuck using state-of-the-art computer analysis software

TTP Group reshuffles top management of Triplan Ingenieur AG

TTP Group reshuffles top management of Triplan Ingenieur AG

Evotec invests in Exscientia to advance AI-driven drug discovery